» Articles » PMID: 17907477

Percutaneous Destructive Pain Procedures on the Upper Spinal Cord and Brain Stem in Cancer Pain: CT-guided Techniques, Indications and Results

Overview
Specialty Neurosurgery
Date 2007 Oct 3
PMID 17907477
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

In the century of science and technology, the average life span has increased, bringing with it an increase in the incidence of degenerative and cancer disease. Intractable pain is usually the main symptom of cancer. With the advancement in technology, there is a large group of patients with intractable pain problems who can benefit from special help medically or surgically. Destructive pain procedures are necessary to control the cancer pain and are based on the lesioning of the pain conducting pathways. Percutaneous cordotomy, trigeminal tractotomy and extralemniscal myelotomy are special methods based on lesioning of the pain conducting pathways. The procedure consists of obtaining direct morphological appearance of the upper spinal cord and surrounding structures by computed tomography (CT). The next step is functional evaluation of the target and its environment by impedance measurement and stimulation. The final step is terminated with controlled lesioning obtained by a radiofrequency system (generator, needles, electrode system). In the last two decades, CT-guided destructive procedures were used as minimally invasive procedures as follows: percutaneous cordotomy (207 patients), trigeminal tractotomy-nucleotomy (65 patients), and extralemniscal myelotomy (16 patients). Most of these patients had cancer pain. Minimally invasive CT-guided destructive pain procedures are still safe and effective operations for relieving intractable cancer pain in selected cases.

Citing Articles

Neurosurgery for mental conditions and pain: An historical perspective on the limits of biological determinism.

Coffey R, Caroff S Surg Neurol Int. 2025; 15():479.

PMID: 39777168 PMC: 11705162. DOI: 10.25259/SNI_819_2024.


Pharmacological Treatments and Therapeutic Drug Monitoring in Patients with Chronic Pain.

De Rosa F, Giannatiempo B, Charlier B, Coglianese A, Mensitieri F, Gaudino G Pharmaceutics. 2023; 15(8).

PMID: 37631302 PMC: 10457775. DOI: 10.3390/pharmaceutics15082088.


The Use of L2 and L3 Lumbar Sympathetic Blockade for Cancer-Related Pain, an Experience and Recommendation in the Oncologic Population.

Spiegel M, Hingula L, Chen G, Legler A, Puttanniah V, Gulati A Pain Med. 2019; 21(1):176-184.

PMID: 31274168 PMC: 7761528. DOI: 10.1093/pm/pnz142.


Surgical/radiological interventions for cancer pain.

Harsh V, Viswanathan A Curr Pain Headache Rep. 2013; 17(5):331.

PMID: 23512723 DOI: 10.1007/s11916-013-0331-1.


Is the WHO analgesic ladder still valid? Twenty-four years of experience.

Vargas-Schaffer G Can Fam Physician. 2010; 56(6):514-7, e202-5.

PMID: 20547511 PMC: 2902929.